Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Evaluation of Overactive Bladder in Male Antidepressant Users: A Prospective Study.

Solmaz V, Albayrak S, Tekatas A, Aksoy D, Gençten Y, İnanır S, Erdemir F.

Int Neurourol J. 2017 Mar 24;21(1):62-67. doi: 10.5213/inj.1732652.326.

2.

Assessing disruptions in adherence to antidepressant treatments after breast cancer diagnosis.

Chou YT, Winn AN, Rosenstein DL, Dusetzina SB.

Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):676-684. doi: 10.1002/pds.4198. Epub 2017 Mar 19.

PMID:
28317314
4.

Trajectories of relapse in randomised, placebo-controlled trials of treatment discontinuation in major depressive disorder: an individual patient-level data meta-analysis.

Gueorguieva R, Chekroud AM, Krystal JH.

Lancet Psychiatry. 2017 Mar;4(3):230-237. doi: 10.1016/S2215-0366(17)30038-X. Epub 2017 Feb 9.

PMID:
28189575
5.

Use of a self-rating scale to monitor depression severity in recurrent GP consultations in primary care - does it really make a difference? A randomised controlled study.

Wikberg C, Westman J, Petersson EL, Larsson ME, André M, Eggertsen R, Thorn J, Ågren H, Björkelund C.

BMC Fam Pract. 2017 Jan 19;18(1):6. doi: 10.1186/s12875-016-0578-9.

6.

Ketamine for depression relapse prevention following electroconvulsive therapy: protocol for a randomised pilot trial (the KEEP-WELL trial).

Finnegan M, Ryan K, Shanahan E, Harkin A, Daly L, McLoughlin DM.

Pilot Feasibility Stud. 2016 Aug 3;2:38. eCollection 2016.

7.

Efficacy and tolerability of vilazodone for major depressive disorder: evidence from phase III/IV randomized controlled trials.

Shi L, Wang J, Xu S, Lu Y.

Drug Des Devel Ther. 2016 Nov 25;10:3899-3907. eCollection 2016.

8.

Bad Medicine: The rise and rise of antidepressants.

Spence D.

Br J Gen Pract. 2016 Nov;66(652):573. No abstract available.

PMID:
27789499
9.

Predicting relapse after antidepressant withdrawal - a systematic review.

Berwian IM, Walter H, Seifritz E, Huys QJ.

Psychol Med. 2017 Feb;47(3):426-437. doi: 10.1017/S0033291716002580. Epub 2016 Oct 27.

10.
11.

Long-term antidepressant use: patient perspectives of benefits and adverse effects.

Cartwright C, Gibson K, Read J, Cowan O, Dehar T.

Patient Prefer Adherence. 2016 Jul 28;10:1401-7. doi: 10.2147/PPA.S110632. eCollection 2016.

12.

Times to Discontinue Antidepressants Over 6 Months in Patients with Major Depressive Disorder.

Jung WY, Jang SH, Kim SG, Jae YM, Kong BG, Kim HC, Choe BM, Kim JG, Kim CR.

Psychiatry Investig. 2016 Jul;13(4):440-6. doi: 10.4306/pi.2016.13.4.440. Epub 2016 Jul 25.

13.

Stability of remission rates in a 3-year follow-up of naturalistic treated depressed inpatients.

Seemüller F, Obermeier M, Schennach R, Bauer M, Adli M, Brieger P, Laux G, Riedel M, Falkai P, Möller HJ.

BMC Psychiatry. 2016 May 20;16:153. doi: 10.1186/s12888-016-0851-4.

14.

Medication use patterns, health care resource utilization, and economic burden for patients with major depressive disorder in Beijing, People's Republic of China.

Zhang L, Chen Y, Yue L, Liu Q, Montgomery W, Zhi L, Wang W.

Neuropsychiatr Dis Treat. 2016 Apr 20;12:941-9. doi: 10.2147/NDT.S97407. eCollection 2016.

15.

Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology.

Goodwin GM, Haddad PM, Ferrier IN, Aronson JK, Barnes T, Cipriani A, Coghill DR, Fazel S, Geddes JR, Grunze H, Holmes EA, Howes O, Hudson S, Hunt N, Jones I, Macmillan IC, McAllister-Williams H, Miklowitz DR, Morriss R, Munafò M, Paton C, Saharkian BJ, Saunders K, Sinclair J, Taylor D, Vieta E, Young AH.

J Psychopharmacol. 2016 Jun;30(6):495-553. doi: 10.1177/0269881116636545. Epub 2016 Mar 15.

16.

Safety of research into severe and treatment-resistant mood disorders: analysis of outcome data from 12 years of clinical trials at the US National Institute of Mental Health.

Nugent AC, Iadarola ND, Miller FG, Luckenbaugh DA, Zarate CA Jr.

Lancet Psychiatry. 2016 May;3(5):436-42. doi: 10.1016/S2215-0366(16)00006-7. Epub 2016 Mar 10.

17.

Vulnerability for new episodes in recurrent major depressive disorder: protocol for the longitudinal DELTA-neuroimaging cohort study.

Mocking RJ, Figueroa CA, Rive MM, Geugies H, Servaas MN, Assies J, Koeter MW, Vaz FM, Wichers M, van Straalen JP, de Raedt R, Bockting CL, Harmer CJ, Schene AH, Ruhé HG.

BMJ Open. 2016 Mar 1;6(3):e009510. doi: 10.1136/bmjopen-2015-009510.

18.

A Dishful of a Troubled Mind: Induced Pluripotent Stem Cells in Psychiatric Research.

Kálmán S, Hathy E, Réthelyi JM.

Stem Cells Int. 2016;2016:7909176. doi: 10.1155/2016/7909176. Epub 2015 Dec 29. Review.

19.

Monitoring patients on chronic treatment with antidepressants between 2003 and 2011: analysis of factors associated with compliance.

Serna MC, Real J, Cruz I, Galván L, Martin E.

BMC Public Health. 2015 Nov 26;15:1184. doi: 10.1186/s12889-015-2493-8.

20.

The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.

Bruno A, Morabito P, Spina E, Muscatello MR.

Curr Neuropharmacol. 2016;14(2):191-9. Review.

Supplemental Content

Support Center